SEC Filing Summary: Entero Therapeutics, Inc. (ENTO)
Business Context and Reporting Period
This Form 8-K, dated October 28, 2025, reports on Entero Therapeutics, Inc.'s (the "Company") status regarding its listing on The Nasdaq Stock Market LLC. The filing addresses the resolution of a compliance deficiency related to the minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).
Key Financial Metrics
The filing references the Company's stockholders' equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024, which was a deficit of ($3,876,738). This figure was below the required minimum of $2.5 million. The filing does not provide current revenue, profit, cash flow, or debt figures for the period ending October 28, 2025.
Material Changes and Compliance Status
- Initial Deficiency: On April 11, 2025, Nasdaq notified the Company of non-compliance due to negative stockholders' equity and failure to meet alternative standards (market value of listed securities or net income).
- Compliance Plan: The Company received an extension until October 8, 2025, to regain compliance.
- Remedial Action: The Company executed a share exchange agreement dated September 30, 2025, with GridAI Corp. This transaction was intended to increase stockholders' equity to at least $2.5 million.
- Resolution: On October 28, 2025, Nasdaq issued a letter confirming the Company is now in compliance with the Equity Rule based on the October 6, 2025, Form 8-K disclosure.
Outlook, Risks, and Contingencies
While compliance has been confirmed, the Nasdaq letter warns that if the Company fails to evidence compliance upon filing its next periodic report, it may be subject to delisting. In such an event, Nasdaq will provide written notification, and the Company may appeal the determination to a Hearings Panel.
Investor Verification Checklist
- Verify the details of the share exchange agreement with GridAI Corp. dated September 30, 2025, and its impact on the balance sheet.
- Review the upcoming periodic report (10-Q or 10-K) to confirm continued compliance with the $2.5 million stockholders' equity requirement.
- Monitor for any future correspondence from Nasdaq regarding potential delisting risks if future filings do not reflect sustained compliance.
- Confirm the current status of the Company's operations and financial health post-transaction, as the filing focuses solely on listing compliance.